2696 — Shanghai Henlius Biotech Share Price
Last trade - 00:00- HK$45.44bn
- HK$48.57bn
- CNY5.72bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 52.53 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -14.81% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.82 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 102.91 | ||
| Price to Sales | 7.28 | ||
| EV to EBITDA | 33.89 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.41% | ||
| Return on Equity | 31.52% | ||
| Operating Margin | 16.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 587.59 | 1,682.47 | 3,214.73 | 5,394.91 | 5,724.45 | 6,088.01 | 5,208.09 | 128.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +50.27 | +21.67 | -32.82 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 24th, 2010
- Public Since
- September 25th, 2019
- No. of Employees
- 3,515
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 543,494,853
- Address
- 11/F, B8 Building, No. 188 Yizhou Road,, SHANGHAI, 200233
- Web
- https://www.henlius.com/
- Phone
- Auditors
- Ernst & Young
Latest News for 2696
Upcoming Events for 2696
Similar to 2696
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
Ab&B Bio Tech Co JS
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:04 UTC, shares in Shanghai Henlius Biotech are trading at HK$83.60. This share price information is delayed by 15 minutes.
Shares in Shanghai Henlius Biotech last closed at HK$83.60 and the price had moved by +263.48% over the past 365 days. In terms of relative price strength the Shanghai Henlius Biotech share price has outperformed the FTSE Developed Asia Pacific Index by +215.01% over the past year.
The overall consensus recommendation for Shanghai Henlius Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreShanghai Henlius Biotech does not currently pay a dividend.
Shanghai Henlius Biotech does not currently pay a dividend.
Shanghai Henlius Biotech does not currently pay a dividend.
To buy shares in Shanghai Henlius Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$83.60, shares in Shanghai Henlius Biotech had a market capitalisation of HK$45.44bn.
Here are the trading details for Shanghai Henlius Biotech:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2696
Based on an overall assessment of its quality, value and momentum Shanghai Henlius Biotech is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shanghai Henlius Biotech is HK$78.50. That is 6.1% below the last closing price of HK$83.60.
Analysts covering Shanghai Henlius Biotech currently have a consensus Earnings Per Share (EPS) forecast of CNY1.84 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Henlius Biotech. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +245.82%.
As of the last closing price of HK$83.60, shares in Shanghai Henlius Biotech were trading +135.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Henlius Biotech PE ratio based on its reported earnings over the past 12 months is 52.53. The shares last closed at HK$83.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Shanghai Henlius Biotech's directors